NCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer

Treatment for metastatic HER2-negative breast cancer is becoming increasingly individualized as more of the tumor landscape is described and drugs are developed to target its pathways. Survival can be prolonged by CDK4/6 inhibitors in patients with hormone receptor–positive tumors and by immunotherapy in those with triple-negative disease. In patients with BRCA1/2 mutations, PARP inhibitors delay disease progression. Antibody–drug conjugates are expected to become critical components of the treatment landscape, and targeted drugs are proving to benefit small subsets of patients.

Disclosures: Dr. Gradishar has disclosed serving as a scientific advisor for AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo Co., Eli Lilly and Company, ImmunoGen, Inc., MacroGenics, Puma Biotechnology, and Seattle Genetics, Inc.; and receiving honoraria from AstraZeneca Pharmaceuticals LP, Biotheranostics, Daiichi-Sankyo Co., ImmunoGen, Inc.

Correspondence: William J. Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center at Northwestern University, 676 North St. Clair Street, Suite 850, Chicago, IL 60611. Email: w-gradishar@northwestern.edu
  • 1.

    Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:307316.

  • 2.

    Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29:15411547.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Llombart-Cussac A, Pérez-García JM, Bellet M, et al. PARSIFAL: a randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor [+]/HER2[-] metastatic breast cancer [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 1007.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Cristofanilli M, Rugo HS, Im SA, et al. Overall survival with palbociclib + fulvestrant in women with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: updated analyses from PALOMA-3 [abstract]. J Clin Oncol 2021;39(Suppl):Abstract 1000.

    • Search Google Scholar
    • Export Citation
  • 5.

    Slamon DJ, Neven P, Chia SKL, et al. Updated overall survival results from the phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with fulvestrant ± ribociclib [abstract]. J Clin Oncol 2021;39(Suppl):Abstract 1001.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380:19291940.

  • 7.

    Juric D, Andre F, Panwar U, et al. Long-term disease control in patients with hormone receptor-positive, PIK3CA-altered advanced breast cancer treated with alpelisib + fulvestrant [abstract]. J Clin Oncol 2021;39(Suppl):Abstract 1054.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 2021;22:489498.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Jhaveri KL, Boni V, Sohn J, et al. Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC) [abstract]. J Clin Oncol 2021;39(Suppl):Abstract 1017.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Linden HM, Campone M, Bardia A, et al. A phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC): AMEERA-1 [abstract]. Presented at 2020 San Antonio Breast Cancer Symposium; December 8–11, 2020. Abstract PD8-08.

    • Search Google Scholar
    • Export Citation
  • 11.

    Bardia A, Kaklamani V, Wilks S, et al. Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer. J Clin Oncol 2021;39:13601370.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Jhaveri KL, Lim E, Hamilton EP, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): results from the EMBER study [abstract]. J Clin Oncol 2021; 39(Suppl):Abstract 1050.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Bardia A, Neven P, Streich G, et al. Elacestrant, an oral selective estrogen receptor degrader vs investigator’s choice of endocrine monotherapy for ER+/HER2– advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy: results of EMERALD phase 3 trial [abstract]. Presented at the 2021 San Antonio Breast Cancer Symposium; December 7–10, 2021. Abstract GS2-02.

    • Search Google Scholar
    • Export Citation
  • 14.

    Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020;396:18171828.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:4459.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Cortés J, Cescon DW, Rugo HS, et al. Final results of KEYNOTE-355: randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Presented at the 2021 San Antonio Breast Cancer Symposium; December 7–10, 2021. Abstract GS1-02.

    • Search Google Scholar
    • Export Citation
  • 17.

    Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019;30:558566.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 2020;31:15261535.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 2020;38:42744282.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol 2020;38:423433.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2017;18:13601372.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Dent R, Kim S, Oliveira M, et al. Double-blind placebo-controlled randomized phase III trial evaluating first-line ipatasertib combined with paclitaxel for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer: primary results from IPATunity130 Cohort A [abstract]. Presented at the 2020 San Antonio Breast Cancer Symposium; December 8–11, 2020. Abstract GS3-04.

    • Search Google Scholar
    • Export Citation
  • 23.

    Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384:15291541.

  • 24.

    Krop I, Juric D, Shimizu T, et al. Datopotamab deruxtecan in advanced/metastatic HER2 negative breast cancer: triple negative breast cancer results from the phase 1 TROPION-PanTumor01 study [abstract]. Presented at the 2021 San Antonio Breast Cancer Symposium: December 7–10, 2021. Abstract GS1-05.

    • Search Google Scholar
    • Export Citation
  • 25.

    Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol 2020;38:18871896.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3912 3912 3912
PDF Downloads 3174 3174 3174
EPUB Downloads 0 0 0